Cell & Gene Therapy Review's Karen Langhauser is joined by Kasturi Sengupta, Ph.D., technical business development representative at Vector Biolabs, to discuss how AAV vector design, serotype selection, and delivery strategies are shaping the future of neuromuscular gene therapy. Kasturi brings with her over 15 years of experience in cell and molecular biology, providing scientific insight and guidance to customers on viral vector design tailored to their specific project interests.